AI isn’t sitting on the sidelines of life sciences anymore. It’s becoming a collaborator.
Across Greater Philadelphia, the BioHealth Capital Region and North Carolina, pharma companies, academic medical centers, CDMOs and startups are teaming up with AI companies to tackle some of the industry’s biggest bottlenecks, from finding drug targets and designing cancer vaccines to navigating FDA filings, improving clinical decisions and identifying the right trial sites.
Why AI Needs Partners
AI may be powerful on its own, but in life sciences, its value depends on what it can do with the right data, expertise and real-world context. That’s where partnerships come in. Life science companies bring proprietary datasets, scientific expertise, clinical access, lab infrastructure and regulatory knowledge. AI companies bring the models, platforms and computational power to turn those assets into insights and action. The result is a new kind of collaboration — one where AI isn’t replacing the scientist, clinician or regulatory expert, but extending what they can do.
5 Patterns Across the Deals
- AI is moving across the entire life sciences value chain. From target discovery and cancer vaccine design to clinical decision support, regulatory filings, manufacturing and healthcare marketing, AI is no longer confined to the research lab.
- Data is becoming the competitive advantage. UNC is generating open cancer datasets, PurpleLab is bringing claims data spanning 330 million patient lives, and BullFrog AI is applying multi-omic data to uncover new therapeutic targets. The models matter, but the data powering them may matter even more.
- Human expertise isn’t going anywhere. These partnerships are largely about augmenting scientists, clinicians and regulatory teams — not replacing them. Novo Nordisk, Annovis and BullFrog AI all emphasize human oversight, validation or final decision-making.
- Academic medicine is becoming a major AI proving ground. Penn Medicine, Johns Hopkins Medicine and UNC Lineberger show how academic institutions are moving beyond research collaborations and putting AI directly into clinical care, medical education and translational research.
- The definition of an “AI partnership” is expanding. The deals span strategic collaborations, grants, licensing agreements, technology integrations and even a $270 million acquisition. In other words, companies are using whatever structure makes sense to bring AI deeper into the business.
1. Novo Nordisk × Anthropic: Bringing Claude Into Drug Discovery
Novo Nordisk will test Claude Science, Anthropic’s AI workbench for scientists, on R&D problems picked by its own teams. It will also use Anthropic’s models to scale AI-driven software development company-wide. CEO Mike Doustdar calls it part of Novo’s push to become “the world’s most AI-driven healthcare company.”
2. UNC Lineberger × OpenAI Foundation: $40M for Smarter Cancer Vaccines
The OpenAI Foundation’s $40 million grant funds UNC Lineberger to analyze hundreds of tumor and immune samples and train AI to pick better targets for personalized cancer vaccines. The team will also compare vaccine formulations in triple-negative breast cancer trials, and the data will be made openly available.
3. Penn Medicine × OpenEvidence: AI Decision Support
Penn Medicine is rolling out OpenEvidence’s clinical AI to more than 10,000 clinicians across seven hospitals. Through the 25-year Botswana-UPenn Partnership, the two will also co-build custom tools with clinicians in Botswana.
4. Johns Hopkins Medicine × OpenEvidence: Training Doctors for the AI Era
Johns Hopkins Medicine is partnering with OpenEvidence to redesign medical education and clinical care for the AI era. It’s the second academic medical center on this list to team up with OpenEvidence.
5. BullFrog AI × Top-5 Global Pharma: New Targets for Depression
Gaithersburg’s BullFrog AI hit key milestones in its first commercial program with a top-5 global pharma, using AI on neuropsychiatric multi-omic data to identify novel targets for major depressive disorder. Schizophrenia and bipolar disorder are next on its list.
6. Annovis Bio × Weave Bio: An AI-Assisted Path to the FDA
Annovis is using Weave Bio’s AI regulatory platform to draft and manage its NDA for buntanetap, its oral Alzheimer’s and Parkinson’s candidate. The goal is to have most of the filing ready before Phase 3 top-line data arrives in March 2027, with Annovis’ own team in full control of what’s submitted.
7. Minaris × Asimov: AI-Native Biology for Gene Therapy Manufacturing
Philadelphia CDMO Minaris is bringing its OXGENE technology to Asimov’s AI-native synthetic biology platform. Together they aim to build stable, high-titer AAV producer cell lines that cut the cost and inconsistency of transient transfection.
8. PurpleLab × Chalice AI: Predictive Intelligence for Healthcare Marketing
Wayne-based PurpleLab is pairing claims data covering 330 million U.S. patient lives with Chalice AI’s custom predictive models. The aim is campaigns built around predicted outcomes rather than static audience lists, in privacy-first environments.
9. Kemp Proteins × NeuImmune: Engineering Glycans by Design
Frederick’s Kemp Proteins is adopting NeuImmune’s geCHO platform: 28 glycoengineered CHO cell lines plus GlyCompare, an explanatory AI tool that links glycan features to biological effects. The pair is also applying it to BARDA-backed antibodies against Ebola and Sudan virus.
10. Agilent × Proscia: A Big Bet on AI-Enabled Digital Pathology
Agilent will acquire Philadelphia’s Proscia in a deal worth up to $270 million, expanding its AI-enabled digital pathology capabilities. It’s a reminder that in AI, the closest partnerships sometimes end in acquisitions.
What to Watch
The partnerships are only the beginning. The real question is what they deliver next.
Annovis is racing toward its March 2027 Phase 3 readout. Novo Nordisk will begin testing Claude Science across real-world R&D problems. UNC Lineberger is building datasets that could shape the next generation of personalized cancer vaccines. And across the region, more companies are figuring out where AI can move a scientific or clinical decision forward.
The bigger shift is already underway: AI is becoming less of a tool scientists use and more of a partner they work with.
Know an AI partnership we missed? Tell us about it — we may feature it in our next roundup.
